insulin icodec/semaglutide First Once-Weekly Basal Approved for Type 2 Diabetes Awiqli® - world's first once-weekly

Ipamorelin stimulates the release and elevates the growth hormone production, which plays a crucial role in various bodily processes, including growth during childhood and adolescence

Lim C-E, Pasternak B, Eliasson B, Danaei G, Ueda P (2022) Use of sodiumglucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists according to the 2019 ESC guidelines and the 2019 ADA/EASD consensus report in a national population of patients with type 2 diabetes

Retatrutide GLP-3 Vial All Retatrutide GLP-3 research Retatrutide (development code LY3437943) is a synthetic, once-weekly triple agonist of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors that has been the subject of peer-reviewed phase 1 and phase 2 randomized controlled trials published in The New England Journal of Medicine, The Lancet, and Nature Medicine, including investigations of body weight, glycemic control, and hepatic steatosis in adult human participants

Frontiers in Aging, 3, 852569

Example code lists used to identify covariates are included in supplementary table S2